Economy May 03

A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. Photo by Brian Snyder/REUTERS
Biogen to replace CEO after Alzheimer’s drug flops

Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer's drug Aduhelm less than a year after the medication's launch triggered a backlash from experts, doctors and insurers.